Add-on biologic a boon for kids with moderate to severe asthma: study
Improved asthma control with dupilumab use also linked to fewer exacerbations, doctors report.
Fortnightly dupilumab with standard therapy leads to rapid and sustained improvements in asthma control for 6-11 year-olds with moderate to severe type 2 asthma, research shows.
International doctors say children who responded to the monoclonal antibody had fewer exacerbations, while quality of life improved for both patients and caregivers.
